Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib.

Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS.

Front Oncol. 2013 Dec 30;3:323. doi: 10.3389/fonc.2013.00323. eCollection 2013.

2.

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.

Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, Schütte K, Verslype C, Walecki J, Malfertheiner P; SORAMIC study group.

Liver Int. 2015 Feb;35(2):620-6. doi: 10.1111/liv.12622. Epub 2014 Jul 8.

PMID:
24930619
3.

Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.

Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group.

Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.

4.

Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.

Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators.

J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23.

PMID:
23707371
5.

Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma.

Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P.

Curr Oncol. 2016 Oct;23(5):e472-e480. Epub 2016 Oct 25.

6.

Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.

Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group).

Liver Int. 2015 Mar;35(3):1036-47. doi: 10.1111/liv.12574. Epub 2014 May 20.

PMID:
24750853
7.

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma.

Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO.

J Hepatocell Carcinoma. 2016 Feb 5;3:1-7. doi: 10.2147/JHC.S62261. eCollection 2016.

8.

Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.

Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group.

PLoS One. 2014 Mar 10;9(3):e90909. doi: 10.1371/journal.pone.0090909. eCollection 2014.

9.

Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.

Wang EA, Stein JP, Bellavia RJ, Broadwell SR.

Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30. Review.

PMID:
28758319
10.

Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.

Memon K, Kulik L, Lewandowski RJ, Gupta R, Ryu RK, Miller FH, Vouche M, Atassi R, Ganger D, Mulcahy MF, Salem R.

J Vasc Interv Radiol. 2013 Aug;24(8):1189-1197.e2. doi: 10.1016/j.jvir.2012.12.025. Epub 2013 Mar 7.

PMID:
23474327
11.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
12.

Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation.

Levi Sandri GB, Ettorre GM, Colasanti M, De Werra E, Mascianà G, Ferraro D, Tortorelli G, Sciuto R, Lucatelli P, Pizzi G, Visco-Comandini U, Vennarecci G.

Hepatobiliary Surg Nutr. 2017 Feb;6(1):44-48. doi: 10.21037/hbsn.2017.01.08.

13.

Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.

Ozkan ZG, Poyanli A, Ucar A, Kuyumcu S, Akyuz F, Keskin S, Saglam S, Yilmaz E, Karaca C, Turkmen C.

Cancer Biother Radiopharm. 2015 Apr;30(3):132-8. doi: 10.1089/cbr.2014.1748. Epub 2015 Mar 11.

PMID:
25760644
14.

Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.

Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette C.

J Gastrointest Oncol. 2015 Oct;6(5):469-78. doi: 10.3978/j.issn.2078-6891.2015.056.

15.

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma.

Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A.

World J Hepatol. 2013 Jul 27;5(7):364-71. doi: 10.4254/wjh.v5.i7.364.

16.

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.

Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH.

Onco Targets Ther. 2017 Sep 26;10:4773-4785. doi: 10.2147/OTT.S137519. eCollection 2017.

17.

Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma.

Woo HY, Kim DY, Heo J, Kim CW, Kim S, Yoon KT, Lim W, Hong YM, Won JY, Lee S, Han KH, Cho M.

Hepatol Res. 2017 Apr;47(5):387-397. doi: 10.1111/hepr.12759. Epub 2016 Aug 2.

PMID:
27272116
18.

Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.

Kwok PC, Leung KC, Cheung MT, Lam TW, Szeto LT, Chou SQ, Chia NH, Tong CM, Yuen PK, Cheung CH, Law CK.

J Gastroenterol Hepatol. 2014 Nov;29(11):1897-904. doi: 10.1111/jgh.12621.

PMID:
24734957
19.

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.

Abdel-Rahman OM, Elsayed Z.

Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2. Review.

PMID:
26905230
20.

Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.

Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M.

Oncology. 2013;84(2):108-14. doi: 10.1159/000342650. Epub 2012 Nov 9.

PMID:
23147476

Supplemental Content

Support Center